1.
Baseline characteristics of population at the time of crizotinib initiation (N=428)
| Characteristics | n | % |
| ECOG PS, Eastern Cooperative Oncology Group performance status. | ||
| Age (year) | ||
| Median (range) | 51 (18−82) | |
| <65 | 377 | 88.1 |
| ≥65 | 51 | 11.9 |
| Sex | ||
| Male | 207 | 48.4 |
| Female | 221 | 51.6 |
| Smoking status | ||
| Former-smoker | 125 | 29.2 |
| Never-smoker | 303 | 70.8 |
| Histology | ||
| Adenocarcinoma | 413 | 96.5 |
| Squamous carcinoma | 4 | 0.9 |
| Large cell | 3 | 0.7 |
| Other | 8 | 1.9 |
| ECOG PS | ||
| 0 | 251 | 58.6 |
| 1 | 148 | 34.6 |
| 2 | 21 | 4.9 |
| 3 | 8 | 1.9 |
| Stage | ||
| IIIA−IIIB | 27 | 6.3 |
| IV | 401 | 93.7 |
| Brain metastasis | ||
| Yes | 95 | 22.2 |
| No | 333 | 77.8 |
| Line of therapy before crizotinib | ||
| 0 | 273 | 63.8 |
| 1 | 88 | 20.6 |
| ≥2 | 67 | 15.6 |
| Metastatic lesions except brain metastasis | ||
| Lung | 190 | 44.4 |
| Pleural | 157 | 36.7 |
| Liver | 69 | 16.1 |
| Bone | 144 | 33.6 |
| Adrenal gland | 28 | 6.5 |
| Lymph node | 281 | 65.7 |
| Others | 36 | 8.4 |